高危透明细胞肾癌辅助治疗:ASSURE随机试验高危亚组的更新结果
ASSURE试验高危亚组更新分析纳入1069例pT3、pT4或淋巴结阳性的透明细胞肾癌患者,比较辅助舒尼替尼、索拉非尼与安慰剂。5年无病生存率分别为47.7%、49.9%和50.0%,舒尼替尼对比安慰剂HR 0.94,索拉非尼对比安慰剂HR 0.90(97.5%CI 0.71-1.14)。5年总生存率分别为75.2%、80.2%和76.5%,均无显著差异,剂量四分位分析亦无差异。
要点
- 高危透明细胞肾癌辅助舒尼替尼或索拉非尼对比安慰剂,5年无病生存率和总生存率均无显著差异。
- 舒尼替尼对比安慰剂5年无病生存HR 0.94;索拉非尼对比安慰剂HR 0.90(97.5%CI 0.71-1.14)。
- 按剂量四分位分析未显示疗效差异。
核心结论
- 在高危透明细胞肾癌患者中,肿瘤预后分级和治疗剂量强度均未改变无病生存或总生存无差异的结果。
研究设计与样本
- 双盲随机安慰剂对照3期试验(ASSURE),纳入美国和加拿大合作组1069例2006至2010年入组的高危透明细胞肾癌患者(pT3、pT4或淋巴结阳性)。
- 患者随机接受1年辅助舒尼替尼50 mg、索拉非尼800 mg每日或等效安慰剂;因不耐受修订为舒尼替尼37.5 mg、索拉非尼400 mg每日或等效安慰剂,无严重不良事件时强制剂量递增。
- 主要终点为无病生存,定义为从随机化至复发、第二原发癌或死亡的时间。
主要发现
- 舒尼替尼组358例(男243例[67.9%],女115例[32.1%]),索拉非尼组355例(男248例[69.9%],女107例[30.1%]),安慰剂组356例(男254例[71.3%],女102例[28.7%]);平均(SD)年龄分别为58.3(10.6)岁、56.8(10.3)岁和57.5(10.4)岁。
- 5年无病生存率:舒尼替尼组47.7%,索拉非尼组49.9%,安慰剂组50.0%;舒尼替尼对比安慰剂HR 0.94,索拉非尼对比安慰剂HR 0.90(97.5%CI 0.71-1.14)。
- 5年总生存率:舒尼替尼组75.2%,索拉非尼组80.2%,安慰剂组76.5%;舒尼替尼对比安慰剂HR 1.06(97.5%CI 0.78-1.45;P=0.66),索拉非尼对比安慰剂HR 0.80(97.5%CI 0.58-1.11;P=0.12)。
- 按剂量四分位分析无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Given recently published results of a 750-patient adjuvant sunitinib trial showing improved disease-free survival (DFS), the appropriate strategy for treating high-risk patients is unclear. We sought to determine whether there is improved disease-free survival benefit to taking the active drug in patients with high-risk (pT3, pT4, node-positive) clear cell renal cancer (ccRCC) in the ASSURE trial (adjuvant sunitinib or sorafenib vs placebo in resected unfavorable renal cell carcinoma [RCC]), the largest adjuvant trial published to date. OBJECTIVE: To evaluate DFS and overall survival (OS) in ccRCC high-risk patients randomized to sunitinib or sorafenib vs placebo among patients with stages comparable to other high-risk adjuvant trials. DESIGN, SETTING, AND PARTICIPANTS: The DFS and OS at 10 years postactivation were calculated for 1069 patients in US and Canadian cooperative groups with high-risk patients who had ccRCC histology and pT3, pT4, or node-positive disease accrued between 2006 and 2010 to the double-blind randomized placebo-controlled phase 3 trial. Outcome analyses by dose quartiles of these patients receiving sunitinib or sorafenib were also performed. INTERVENTIONS: Patients received 1 year of adjuvant sunitinib (50 mg), sorafenib (800 mg) daily, or equivalent placebo. The study was amended for patient intolerance to sunitinib (37.5 mg), sorafenib (400 mg) daily, or equivalent placebo with mandatory dose escalation if no serious adverse effects were experienced. MAIN OUTCOMES AND MEASURES: Disease-free survival, defined as time from randomization to recurrence, second primary cancer, or death. RESULTS: Of 1069 patients, 358 (243 [67.9%] men, 115 [32.1%] women) received sunitinib, 355 (248 [69.9%] men, 107 [30.1%] women) received sorafenib, and 356 (254 [71.3%] men, 102 [28.7%] women) received placebo as adjuvant therapy. The mean (SD) age for each group was 58.3 (10.6) years, 56.8 (10.3) years, and 57.5 (10.4) years, respectively. Five-year DFS rates were 47.7%, 49.9%, and 50.0%, respectively for sunitinib, sorafenib, and placebo (HR, 0.94 for sunitinib vs placebo; and HR, 0.90; 97.5% CI, 0.71-1.14 for sorafenib vs placebo), with 5-year OS of 75.2%, 80.2%, and 76.5% (HR, 1.06; 97.5% CI, 0.78-1.45; P = .66, sunitinib vs placebo; and HR, 0.80; 97.5% CI, 0.58-1.11; P = .12 for sorafenib vs placebo). There was no difference by dose quartile. CONCLUSIONS AND RELEVANCE: Neither prognostic category of the tumor nor dose intensity of therapy altered the lack of difference in DFS or OS in this population of patients with high-risk ccRCC. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00326898.
引用
- Haas NB, Manola J, Dutcher JP, et al. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017. PMID: 28278333. doi:10.1001/jamaoncol.2017.0076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。